Snake venoms and envenomation : modern trends and future prospects / editors, Yuri N. Utkin, and Arcadius V. Krivoshein (Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia, and others).

Includes bibliographical references and index.

Print version record and CIP data provided by publisher.

SNAKE VENOMS AND ENVENOMATION MODERN TRENDS AND FUTURE PROSPECTS; SNAKE VENOMS AND ENVENOMATION MODERN TRENDS AND FUTURE PROSPECTS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; SECTION ONE: GENERAL ASPECTS; Chapter 1: SNAKES: DIVERSITY, EPIDEMIOLOGY AND ENVENOMATION; ABSTRACT; GENERAL ASPECTS; EPIDEMIOLOGY AND ENVENOMATION; South Asia; Africa; Europe; Americas; Australia; CONCLUSION; REFERENCES; Chapter 2: VENOMS FROM "NON-VENOMOUS" SNAKES: REAR-FANGED SNAKE VENOMS AS SOURCES OF NOVEL COMPOUNDS; ABSTRACT; INTRODUCTION

BIOLOGY OF REAR-FANGED SNAKES: ITS RELEVANCE TO TOXINOLOGISTSDiversity; Gland Structure -- The Duvernoy's Venom Gland; Venom Yields; COMPOSITION OF VENOM FROM REAR-FANGED SNAKES; Analysis of Venoms; Mass Spectrometry, Proteomic Analysis and Transcriptomic Analyses ofRear-Fanged Snake Venoms; Enzymes; PIII Metalloprotease; Matrix Metalloproteinase; Serine Proteinase; Acetylcholinesterase (AChE); Phospholipase A2; Non-Enzymatic Toxins; Cysteine-Rich Secretory Proteins (CRiSPs); Three-Finger Toxins; Other Components; DRUG DEVELOPMENT POTENTIAL; CONCLUSION AND FUTURE DIRECTIONS; REFERENCES

Chapter 3: VENOM PRODUCTION IN THE 21ST CENTURYABSTRACT; INTRODUCTION; LEGAL CONSIDERATIONS; SAFETY; HUSBANDRY; Biology of the Animals; New Specimens; Feeding; Disease Control; Cleaning/Disinfecting; Record Keeping; Breeding; EXTRACTIONS; REFERENCES; SECTION TWO: CLINICAL AND PATHOPHYSIOLOGICAL ASPECTS; Chapter 4: EXTENDING THE USE OF SNAKE VENOMS TO THERAPEUTICS; ABSTRACT; INTRODUCTION; HISTORICAL USE; DRUG QUALITY; DRUG ENGINEERING; ROUTE OF ADMINISTRATION OPTIONS; PRODUCT PROTECTION STRATEGIES; Patent Term Extensions; Orphan Drug Status

New Chemical/Molecular Entities (NCE/NME) Market ExclusivityBiologic Exclusivity; PRECLINICAL ANIMAL STUDIES; REGULATORY STRATEGY; CLINICAL TRIALS; CONCLUSION; REFERENCES; Chapter 5: PATHOPHYSIOLOGICAL SIGNIFICANCE AND THERAPEUTIC IMPLICATIONS OF RUSSELL'S VIPER VENOM PROTEINS AND PEPTIDES AFFECTING BLOOD COAGULATION; ABSTRACT; INTRODUCTION; HEMOSTATICALLY ACTIVE PROTEINS AND PEPTIDES FROM RVV; Procoagulant Proteins Isolated from RVV: Structure-Functional Propertiesand Mechanisms of Action; Factor X Activators; Factor V Activators; Thrombin-Like Enzymes; Prothrombin Activators

Anticoagulant Proteins from RVV: Structure-Functional Properties andMechanisms of ActionAnticoagulant Proteins Possessing Enzymatic Activity; Phospholipase A2 (PLA2) Enzymes; Fibrino(geno)lytic Proteases; Non-Enzymatic Anticoagulant Proteins/Peptides; Kunitz-Type Serine Protease Inhibitors; C-Type Lectin Like Proteins; An Apoptosis-Inducing Anticoagulant Peptide; Pharmacological Properties and Toxicity of Procoagulant and Anticoagulant Proteins/Peptides Purified from RVV; Biomedical Applications of RVV Proteins/Peptides Affecting Hemostasis; CONCLUSION; ACKNOWLEDGMENTS; REFERENCES

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide